Johnson & Johnson Receives FDA Approval for Balversa in FGFR-Altered Urothelial Carcinoma

Johnson & Johnson today announced that the FDA has approved Balversa (erdafitinib) for the treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations who have progressed during or following at least one line of prior platinum-containing chemotherapy.